# Use of Combined Antiretroviral Therapy to Determine Sites of Persistent HIV Infection

> **NCT00001644** · PHASE1 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 42 (actual)

## Conditions studied

- HIV Infection

## Interventions

- **DRUG:** Indinavir
- **DRUG:** Zidovudine
- **DRUG:** Lamivudine
- **DRUG:** Nevirapine
- **PROCEDURE:** Blood testing
- **PROCEDURE:** Lymph node biospy
- **PROCEDURE:** Leukapheresis

## Key facts

- **NCT ID:** NCT00001644
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1997-03-03
- **Primary completion:** 2010-02-17
- **Final completion:** 2010-02-17
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2017-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00001644

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00001644, "Use of Combined Antiretroviral Therapy to Determine Sites of Persistent HIV Infection". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00001644. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*